Coprelotamab

DB16380InvestigationalProtein Based Therapies

Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Code names: GB-221

Resolves to

Compound

UNIIXQ7509L801CAS2348469-84-9

Targets

P04626ERBB2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Coprelotamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account